The association of functional polymorphism of matrix metalloproteinase-9 gene (rs3918242) with schizophrenia: a meta-analysis

References

• Ali, F. T., Abd El-Azeem, E. M., Hamed, M. A., Ali, M. A. M., Abd Al-Kader, N. M., & Hassan, E. A. (2017). Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: Pathophysiological and phenotypic implications. Schizophrenia Research, 188, 98–109. doi:10.1016/j.schres.2017.01.016
   PubMed Web of Science ®Google Scholar
• Bienkowski, P., Samochowiec, J., Pelka-Wysiecka, J., Grzywacz, A., Skibinska, M., Jasiewicz, A., … Samochowiec, A. (2015). Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtype. Pharmacological Reports: PR, 67, 442–445. doi:10.1016/j.pharep.2014.11.007
   PubMed Web of Science ®Google Scholar
• Birnbaum, R., & Weinberger, D. R. (2017). Genetic insights into the neurodevelopmental origins of schizophrenia. Nature Reviews Neuroscience, 18, 727–740. doi:10.1038/nrn.2017.125
   PubMed Web of Science ®Google Scholar
• Davis, J., Eyre, H., Jacka, F. N., Dodd, S., Dean, O., McEwen, S., … Amminger, P. (2016). A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neuroscience and Biobehavioral Reviews, 65, 185–194. doi:10.1016/j.neubiorev.2016.03.017
   PubMed Web of Science ®Google Scholar
• DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7, 177–188. doi:10.1016/0197-2456(86)90046-2
   PubMedGoogle Scholar
• Devanarayanan, S., Nandeesha, H., Kattimani, S., & Sarkar, S. (2016). Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: A case control study. Clinical Chemistry and Laboratory Medicine, 54, 447–452. doi:10.1515/cclm-2015-0212
   PubMed Web of Science ®Google Scholar
• Domenici, E., Wille, D. R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A., … Turck, C. W. (2010). Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One, 5, e9166. doi:10.1371/journal.pone.0009166
   PubMed Web of Science ®Google Scholar
• Egger, M., Davey Smith, G., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629–634. doi:10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• Groszewska, A., Kapelski, P., Skibinska, M., & Hauser, J. (2011). [Family based association study of MMP-9 gene-1562C > T polymorphism in schizophrenia]. Psychiatria Polska, 45, 317–324. https://www.ncbi.nlm.nih.gov/pubmed/22232962/
   PubMed Web of Science ®Google Scholar
• Han, H., He, X., Tang, J., Liu, W., Liu, K., Zhang, J., … Chen, X. (2011). The C(-1562)T polymorphism of matrix metalloproteinase-9 gene is associated with schizophrenia in China. Psychiatry Research, 190, 163–164. doi:10.1016/j.psychres.2011.04.026
   PubMed Web of Science ®Google Scholar
• Higgins, J. P., & Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21, 1539–1558. doi:10.1002/sim.1186
   PubMed Web of Science ®Google Scholar
• Huntley, G. W. (2012). Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nature Reviews Neuroscience, 13, 743–757. doi:10.1038/nrn3320
   PubMed Web of Science ®Google Scholar
• Kumarasinghe, N., Beveridge, N. J., Gardiner, E., Scott, R. J., Yasawardene, S., Perera, A., … Tooney, P. A. (2013). Gene expression profiling in treatment-naive schizophrenia patients identifies abnormalities in biological pathways involving AKT1 that are corrected by antipsychotic medication. The International Journal of Neuropsychopharmacology, 16, 1483–1503. doi:10.1017/S1461145713000035
   PubMed Web of Science ®Google Scholar
• Lepeta, K., & Kaczmarek, L. (2015). Matrix metalloproteinase-9 as a novel player in synaptic plasticity and schizophrenia. Schizophrenia Bulletin, 41, 1003–1009. doi:10.1093/schbul/sbv036
   PubMed Web of Science ®Google Scholar
• Lepeta, K., Purzycka, K. J., Pachulska-Wieczorek, K., Mitjans, M., Begemann, M., Vafadari, B., … Dziembowska, M. (2017). A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms. EMBO Molecular Medicine, 9, 1100–1116. doi:10.15252/emmm.201707723
   PubMed Web of Science ®Google Scholar
• Li, Z., Chen, J., Yu, H., He, L., Xu, Y., Zhang, D., … Shen, J. (2017). Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia. Nature Genetics, 49, 1576–1583. doi:10.1038/ng.3973
   PubMed Web of Science ®Google Scholar
• Nagase, H., & Woessner, J. F. Jr. (1999). Matrix metalloproteinases. The Journal of Biological Chemistry, 274, 21491–21494. doi:10.1074/jbc.274.31.21491
   PubMed Web of Science ®Google Scholar
• Niitsu, T., Ishima, T., Yoshida, T., Hashimoto, T., Matsuzawa, D., Shirayama, Y., … Iyo, M. (2014). A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Research, 215, 268–273. doi:10.1016/j.psychres.2013.12.009
   PubMed Web of Science ®Google Scholar
• Opdenakker, G., Van den Steen, P. E., & Van Damme, J. (2001). Gelatinase B: A tuner and amplifier of immune functions. Trends in Immunology, 22, 571–579. doi:10.1016/S1471-4906(01)02023-3
   PubMed Web of Science ®Google Scholar
• Rahimi, S., Sayad, A., Moslemi, E., Ghafouri-Fard, S., & Taheri, M. (2017). Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients. Metabolic Brain Disease, 32, 1537–1542. doi:10.1007/s11011-017-0043-z
   PubMed Web of Science ®Google Scholar
• Rybakowski, J. K., Skibinska, M., Kapelski, P., Kaczmarek, L., & Hauser, J. (2009). Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia. Schizophrenia Research, 109, 90–93. doi:10.1016/j.schres.2009.02.005
   PubMed Web of Science ®Google Scholar
• Rybakowski, J. K., Skibinska, M., Suwalska, A., Leszczynska-Rodziewicz, A., Kaczmarek, L., & Hauser, J. (2011). Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene and response to lithium prophylaxis in bipolar patients. Human Psychopharmacology, 26, 168–171. doi:10.1002/hup.1182
   PubMed Web of Science ®Google Scholar
• Schizophrenia Working Group of the Psychiatric Genomics C. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511, 421–427. doi:10.1038/nature13595
   PubMed Web of Science ®Google Scholar
• Schizophrenia: Fact Sheet. [accessed on 30 November 2017]. World Health Organization; [updated April 2016]. Retrieved from https://www.who.int/en/news-room/fact-sheets/detail/schizophrenia
   Google Scholar
• Shibasaki, C., Takebayashi, M., Itagaki, K., Abe, H., Kajitani, N., Okada-Tsuchioka, M., & Yamawaki, S. (2016). Altered serum levels of matrix metalloproteinase-2 in response to electroconvulsive therapy for mood disorders. The International Journal of Neuropsychopharmacology, 19, 9. doi:10.1093/ijnp/pyw019
   Google Scholar
• Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., … Correll, C. U. (2017). Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectrums, 22, 415–426. doi:10.1017/S1092852916000638
   PubMed Web of Science ®Google Scholar
• St Jean, P. L., Zhang, X. C., Hart, B. K., Lamlum, H., Webster, M. W., Steed, D. L. … (1995). Characterization of a dinucleotide repeat in the 92 kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease. Annals of Human Genetics, 59, 17–24. doi:10.1111/j.1469-1809.1995.tb01602.x
   PubMed Web of Science ®Google Scholar
• Supplementary material to the Cochrane Handbook. Chapter 13. Non-randomized studies Newcastle-Ottawa scale for assessing quality of a cohort study. [accessed on 30 November 2017]. Cochrane Training; Retrieved from http://training.cochrane.org/supplementary-material-cochrane-handbook
   Google Scholar
• Vafadari, B., Salamian, A., & Kaczmarek, L. (2016). MMP-9 in translation: From molecule to brain physiology, pathology, and therapy. Journal of Neurochemistry, 139(2), 91–114. doi:10.1111/jnc.13415
   PubMedGoogle Scholar
• Xiang, Y. Q., Zheng, W., Wang, S. B., Yang, X. H., Cai, D. B., Ng, C. H., … Xiang, Y. T. (2017). Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 27, 8–18. doi:10.1016/j.euroneuro.2016.11.012
   PubMed Web of Science ®Google Scholar
• Zhang, B., Ye, S., Herrmann, S. M., Eriksson, P., de Maat, M., Evans, A., … Hamsten, A. (1999). Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 99, 1788–1794. doi:10.1161/01.CIR.99.14.1788
   PubMed Web of Science ®Google Scholar